Your browser doesn't support javascript.
Triple combination therapy in patients infected with COVID-19
JPRN; 27/02/2020; TrialID: JPRN-jRCTs031190227
Clinical Trial Register | ICTRP | ID: ictrp-JPRN-jRCTs031190227
ABSTRACT

Condition

patients infected with COVID-19
Coronavirus;Coronavirus

Intervention

oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir

Primary 

outcome:

expected value and 95% CI of ratio of C-reactive protein before versus after the treatment

Criteria

Inclusion criteria positive result for COVID-19 detection test
fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan
hospital admission

Exclusion criteria past history of hypersensitivity to lopinavir, ritonavir, hydroxychloroquine or oseltamivir
pregnancy
Collection: Clinical trial registers Database: ICTRP Year: 2020 Document Type: Clinical Trial Register

Similar

MEDLINE

...
LILACS

LIS

Collection: Clinical trial registers Database: ICTRP Year: 2020 Document Type: Clinical Trial Register